Does Pregabalin Have Neuropsychotropic Effects?: A Short Perspective

Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and sleep enhancement effects, which could be applicable in the treatment of a variety of psychiatric disorders. There have been consistent reports that unexplained somatic symptoms (i.e., pain) may be a part of psychiatric disorders such as major depressive disorder (MDD) and anxiety disorders. Previous researches have also suggested the possible therapeutic potential of anticonvulsants as augmentation therapy or monotherapy in the treatment of mood disorders and anxiety disorders. Hence this short perspective tries to prompt and facilitate a shifting of researchers’ attention to potential neuropsychotropic drug role of pregabalin to treat a wide range of neuropsychiatric disorders.

KEY WORDS: Pregabalin, Analgesic, Anxiolytic, Anticonvulsant, Psychiatric disorders.

Pregabalin is a newly developed synthetic gamma-aminobutyric acid (GABA) that is approved for the treatment of fibromyalgia and several neuropathy. It has been proven to show analgesic, anxiolytic, anticonvulsant and sleep enhancement effects, which could be applicable in the treatment of a variety of psychiatric disorders. There have been consistent reports that unexplained somatic symptoms (i.e., pain) may be a part of psychiatric disorders such as major depressive disorder (MDD) and anxiety disorders. Previous researches have also suggested the possible therapeutic potential of anticonvulsants as augmentation therapy or monotherapy in the treatment of mood disorders and anxiety disorders. Hence this short perspective tries to prompt and facilitate a shifting of researchers’ attention to potential neuropsychotropic drug role of pregabalin to treat a wide range of neuropsychiatric disorders.

KEY WORDS: Pregabalin, Analgesic, Anxiolytic, Anticonvulsant, Psychiatric disorders.

Introduction

Pregabalin is a new synthetic molecule and a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA). Pregabalin does not bind directly to GABA_A, GABA_B, or benzodiazepine receptors. In addition it does not augment GABA_A responses in cultured neurons, alter rat brain GABA concentration or have acute effects on GABA uptake or degradation. However, it was found that prolonged application of pregabalin increases the density of GABA transporter protein as well as the rate of functional GABA transport in cultured neurons. Pregabalin has no involvement with serotonin and dopamine receptors and does not inhibit dopamine, serotonin, or noradrenaline reuptake. It has no effects on sodium channels, opiate receptors, and cyclooxygenase enzyme activity.

Pregabalin is characterized by its potent high-affinity binding to the α2-δ subunit on voltage-gated calcium channels,12 and is approved for management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia, adjunctive therapy for adult patients with partial onset seizures and management of fibromyalgia by the United States Food and Drug Administration (U.S. FDA).3-6

The drug may have a strong potential as one of promising neuropsychotropic agents in the monotherapy or augmentation treatment of various neuropsychiatric disorders based on its currently available preclinical and clinical data. Hence this short perspective will review the potential neuropsychotropic effects of pregabalin.

Preclinical Evidence

The recent study of brief treatment with alprazolam initiated immediately after exposure to a traumatizing experience revealed that treatment effectively curbed short-
Pregabalin for Psychiatry

term anxiety-like behaviors, but had no prevention value and caused a statistically significant increase in individual vulnerability to a trauma-reminder and even more so to re-exposure to the index stressor. In addition, benzodiazepines have been found not to be associated with the significant treatment effects on trauma-related anxiety symptoms. However, pregabalin was found to be valuable in the alleviation of anxiety symptoms associated with traumatic insults without a tendency of vulnerability to subsequent stress in a preclinical study.

Pregabalin was also excellent in sleep efficiency as showing an enhancement of slow-wave sleep, reduction of the number of midnight awakenings, rapid eye movement sleep and sleep-onset latency, which are commonly seen in depression, anxiety and pain disorders. In addition, pregabalin demonstrated comparable to placebo in cognitive and psychomotor measures, while it was significantly superior to alprazolam.

Pregabalin is a GABA analogue without abuse potential, although the action mechanism is not same with benzodiazepine agents. This property is important in patients who need to withdraw benzodiazepine or may have abuse propensity. Although the proper principal mechanism of pregabalin’s effect on psychiatric disorders may not be fully explained, the modulation of calcium channels by which reduction of excitatory neurotransmitters release should account for its usefulness for various psychiatric disorders. It is in line with one of the action mechanisms of tricyclic antidepressants (TCAs) that have proven effectiveness in the treatment of depression, anxiety and pain diseases.

Several line of preclinical data have also suggested the neuroprotective effect of pregabalin by anti-apoptotic and anti-inflammatory actions, which is useful in protection of cognitive function in patients with depression and geriatric psychiatric population. The effects of the long-term exposure to pregabalin on neuronal damage and epileptogenesis induced by lithium-pilocarpine induced status epilepticus in which the effects of pregabalin was assessed in hippocampus and piriform and entorhinal cortices in rat brain sections. In the study, pregabalin induced neuroprotection in layer II of piriform cortex and layers III-IV of ventral entorhinal cortex of adult rats. The potential neuroprotective effect of pregabalin may add another optional treatment in the area of brain injury, cognitive decline in affective disorders, neurodegenerative disease and dementias.

Clinical Evidence

As stated, pregabalin has been U.S. FDA-approved medication for fibromyalgia, which is interesting since fibromyalgia and major depressive disorder (MDD) share some commonalities. Numerous studies have found that fibromyalgia patients are at increased risk for a lifetime history of MDD as compared to normal community samples. Also, patients with fibromyalgia and MDD share symptomatologic similarities. Depressed mood, poor expression of emotion, decreased energy level, anergia, fatigue, easy upset to psychosocial stressors, aberration of sleep architectures and multiple vague somatic symptoms. Furthermore, the number of tender points in patients with fibromyalgia has been found to be correlated with depressive symptoms such as depressed mood, fatigue, disability, pain, and somatic symptoms as well as being connected with functional impairments.

Recently an emerging evidence of potential role of pregabalin in the treatment of psychiatric disorders such as generalized anxiety disorder (GAD) and social anxiety disorder (SAD) has been available. The potential anti-depressive and anti-anxiety effects of pregabalin have been established in a number of randomized, placebo-controlled clinical trials (RCTs). In the first RCT of pregabalin for GAD, the mean baseline-to-endpoint decreases in total Hamilton Anxiety Rating Scale (HARS) score in patients with 600 mg/d of pregabalin (-44.4%) were significantly greater than the decrease in those given placebo (-29.7%), while it was not significantly different comparing with lorazepam. This trend was observed as early as the week 1 continuing till the end of the study, which was replicated in a subsequent similarly designed 4-week RCT: pregabalin was significantly superior over placebo (mean difference=3.9, p=0.001) as measured by HARS. The superiority of pregabalin along with rapid improvement over placebo was consistently demonstrated in other RCTs, indicating that pregabalin may be clearly useful and has definite clinical evidence for GAD. Interestingly, pregabalin 400 or 600 mg/d was compared with venlafaxine 75 mg/d, or placebo for 6-week (n=421). Pregabalin at both dosages was found be equivalent to the effect of venlafaxine in improvement of HARS with significant differences comparing with placebo. Aforementioned findings ultimately suggest that pregabalin has similar and comparable efficacy with contemporary antidepressant and benzodiazepines as well as having partly favorable adverse events profile compared to benzodiazepines in the treatment of GAD. Although it was not robust as much as seen in GAD trials, pregabalin 600 mg/d was also effective in the treatment of SAD. In line with such RCTs, the effect size (ES) of pregabalin (ES=0.5) for GAD treatment was found be higher than contemporary antidepressants, serotonin-norepinephrine reuptake inhibitors (SNRIs)(ES=0.42) and selective serotonin reuptake inhibitors (SSRIs)(ES=0.36), and benzodiazepines.
According a post-hoc analysis of the existing clinical trial database, pregabalin at doses of 150 mg/d (32.1%), 300-450 mg/d (40.1%) and 600 mg/d (36.7%) was associated with statistically significant improvement in end-point Hamilton Depression Rating Scale-17 item (HAM-D-17) scores compared to placebo (22.8%). Moreover, pregabalin retained superior efficacy even in patients with more prominent depressive symptoms compared to placebo, especially demonstrating the most beneficial response with pregabalin 300-450 mg/d. This finding may indicate the potential of pregabalin as augmentation therapy for patients with treatment resistance, partially responding to current antidepressants or with comorbid anxiety disorders when subsequent RCTs replicate similar results.

Pregabalin was also effective in the treatment of benzodiazepine withdrawal symptoms in even chronic abusers. This issue is in particular important since many psychiatric patients as well as those seen in general practice have been easily exposed to abuse or dependence, which may lead to comorbid psychiatric and medical conditions as well as increment of individual and public health care costs. Hence pregabalin may be quite helpful when it could be applicable to the biological detoxification programs.

In the author’s clinical experience, pregabalin was very useful as augmentation therapy in the treatment of post-traumatic stress disorder (PTSD) patients who were partially responsive to current antidepressants as well. The action mode of pregabalin, that is, a reduction of excitatory neurotransmitters such as glutamate fits well with major symptoms of PTSD, i.e., hypervigilance and hyperarousal.

Future Direction and Conclusion

We may expect a substantial role of pregabalin for patients with depression, anxiety disorders, substance abuse and dependence, aggression and violence, interictal psychosis, sleep disturbance, unexplained somatic complaints (predominantly widespread pain), PTSD, neurodegenerative diseases and bipolar affective disorders (Figure 1).

Future researches should include whether or not pregabalin has early improvement effect in depression or anxiety disorders and any treatment effects as augmentation therapy for such patients who did not respond to conventional treatment options. Predictor analysis on response to pregabalin will be intriguing well. Given methodological pitfalls in currently available data, additional works are also needed to determine whether these favorable findings for pregabalin hold true over the long-term period, and whether patients having several comorbid psychiatric disorders are also responsive to pregabalin. Direct comparison studies will be also necessary to confirm differential outcomes between pregabalin and contemporary treatment regimes.

Acknowledgments

This work was supported by a grant from the Medical Research Center, Korea Science and Engineering Foundation, Republic of Korea (R13-2002-005-04001-0).

REFERENCES

1. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-1030.
2. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805-1815.
3. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-1273.
4. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-514.
5. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-431.
6. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805.
7. Zolar J, Matar MA, Hergane G, Kaplan Z, Cohen H. Brief post-stressor treatment with pregabalin in an animal model for PTSD: short-term anxiolytic effects without long-term anxiogenic effect. Eur Neuropsychopharmacol 2008;18:653-666.
8. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with

1. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 2005;62:1022-1030.
2. Gajraj NM. Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805-1815.
3. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:1264-1273.
4. Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP Jr, Martin SA, et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008;35:502-514.
5. Crofford LJ, Mease PJ, Simpson SL, Young JP Jr, Martin SA, Haig GM, et al. Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin. Pain 2008;136:419-431.
6. Arnold LM, Russell IJ, Diri EW, Duan WR, Young JP Jr, Sharma U, et al. A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008;9:792-805.
7. Zolar J, Matar MA, Hergane G, Kaplan Z, Cohen H. Brief post-stressor treatment with pregabalin in an animal model for PTSD: short-term anxiolytic effects without long-term anxiogenic effect. Eur Neuropsychopharmacol 2008;18:653-666.
8. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with
alprazolam and placebo. Sleep 2005;28:187-193.
9. Hindmarch I, Trick L, Riddout F. A double-blind, placebo- and positive-
internal-controlled (alprazolam) investigation of the cognitive and psy-
chomotor profile of pregabalin in healthy volunteers. Psychopharmacology (Berl) 2005;183:133-143.
10. Ha KY, Kim YH, Rhyu KW, Kwon SE. Pregabalin as a neuropro-
tector after spinal cord injury in rats. Eur Spine J 2006;17:864-872.
11. André V, Rigoulot MA, Koning E, Fernando A, Nehlig A. Long-term
pregabalin treatment protects basal cortices and delays the occurrence
of spontaneous seizures in the lithium-pilocarpine model in the rat.
Epilepsia 2003;44:893-903.
12. Ratcliffe GE, Emms MW, Belik SL, Sareen J. Chronic pain conditions
and suicidal ideation and suicide attempts: an epidemiologic perspec-
tive. Clin J Pain 2008;24:204-210.
13. Pae CU, Luyten P, Marks DM, Han C, Park SH, Patkar AA, et al. The
relationship between fibromyalgia and major depressive disorder: a
comprehensive review. Curr Med Res Opin 2008;24:2359-2371.
14. Lundberg G, Gerdle B. Tender point scores and their relations to signs
of mobility, symptoms, and disability in female home care personnel
and the prevalence of fibromyalgia syndrome. J Rheumatol 2002;29:
603-613.
15. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler
R, et al. Pregabalin in generalized anxiety disorder: a placebo-controll-
ed trial. Am J Psychiatry 2003;160:533-540.
16. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein
MB, et al. Efficacy of the novel anxiolytic pregabalin in social anxiety
disorder: a placebo-controlled, multicenter study. J Clin Psychophar-
macol 2004;24:141-149.
17. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK,
Targum SD, et al. A randomized, double-blind, placebo-controlled,
fixed-dose, multicenter study of pregabalin in patients with generaliz-
ed anxiety disorder. J Clin Psychopharmacol 2003;23:240-249.
18. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin
in depressive symptoms associated with generalized anxiety disorder:
a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008;18:
422-430.
19. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in
the treatment of generalized anxiety disorder: double-blind, placebo-
controlled comparison of BID versus TID dosing. J Clin Psychophar-
macol 2005;25:151-158.
20. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Ef-
cicacy and safety of pregabalin in the treatment of generalized anxiety
disorder: a 6-week, multicenter, randomized, double-blind, placebo-
controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry
2006;67:771-782.
21. Hidalgo RB, Tupper LA, Davidson JR. An effect-size analysis of phar-
cmacologic treatments for generalized anxiety disorder. J Psychophar-
cmol 2007;21:864-872.
22. Biermann T, Bleich S, Kornhuber J, Hillemacher T. Pregabalin in
benzodiazepine withdrawal. Pharmacopsychiatry 2007;40:292-293.
23. Oulis P, Konstantakopoulos G, Kouzoupis AV, Masdrakis VG, Kara-
katsanis NA, Karapoulou E, et al. Pregabalin in the discontinuation of
long-term benzodiazepines’ use. Hum Psychopharmacol 2008;23:337-
340.
24. Stevens JC, Pollack MH. Benzodiazepines in clinical practice: consid-
eration of their long-term use and alternative agents. J Clin Psychi-
try 2005;66 Suppl 2:21-27.
25. Pae CU, Marks DM, Han C, Masand PS, Patkar AA. Pregabalin
augmentation of antidepressants in patients with accident-related post-
traumatic stress disorder: an open label pilot study. Int Clin Psycho-
pharmacol 2009;24:29-33.
26. Cortese BM, Phan KL. The role of glutamate in anxiety and related
disorders. CNS Spectr 2005;10:820-830.